| Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice K Tamminen, S Lappalainen, L Huhti, T Vesikari, V Blazevic PloS one 8 (7), e70409, 2013 | 107 | 2013 |
| A comparison of immunogenicity of norovirus GII‐4 virus‐like particles and P‐particles K Tamminen, L Huhti, T Koho, S Lappalainen, VP Hytönen, T Vesikari, ... Immunology 135 (1), 89-99, 2012 | 92 | 2012 |
| Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo S Lappalainen, AR Pastor, K Tamminen, V López-Guerrero, ... Human vaccines & immunotherapeutics 10 (7), 2039-2047, 2014 | 55 | 2014 |
| Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles S Lappalainen, K Tamminen, T Vesikari, V Blazevic Human vaccines & immunotherapeutics 9 (9), 1991-2001, 2013 | 43 | 2013 |
| Comparison of human saliva and synthetic histo-blood group antigens usage as ligands in norovirus-like particle binding and blocking assays H Uusi-Kerttula, K Tamminen, M Malm, T Vesikari, V Blazevic Microbes and Infection 16 (6), 472-480, 2014 | 38 | 2014 |
| Norovirus-specific memory T cell responses in adult human donors M Malm, K Tamminen, T Vesikari, V Blazevic Frontiers in Microbiology 7, 213130, 2016 | 35 | 2016 |
| Rotavirus recombinant VP6 nanotubes act as an immunomodulator and delivery vehicle for norovirus virus-like particles M Malm, K Tamminen, S Lappalainen, T Vesikari, V Blazevic Journal of immunology research 2016, 2016 | 34 | 2016 |
| Live baculovirus acts as a strong B and T cell adjuvant for monomeric and oligomeric protein antigens S Heinimäki, K Tamminen, M Malm, T Vesikari, V Blazevic Virology 511, 114-122, 2017 | 30 | 2017 |
| Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition M Malm, K Tamminen, S Lappalainen, H Uusi-Kerttula, T Vesikari, ... Clinical and Vaccine Immunology 22 (6), 656-663, 2015 | 29 | 2015 |
| Seroprevalence and SARS-CoV-2 cross-reactivity of endemic coronavirus OC43 and 229E antibodies in Finnish children and adults K Tamminen, M Salminen, V Blazevic Clinical immunology 229, 108782, 2021 | 27 | 2021 |
| Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography L Huhti, K Tamminen, T Vesikari, V Blazevic Archives of virology 158, 933-942, 2013 | 27 | 2013 |
| Rotavirus VP6 as an Adjuvant for Bivalent Norovirus Vaccine Produced in Nicotiana benthamiana M Malm, A Diessner, K Tamminen, M Liebscher, T Vesikari, V Blazevic Pharmaceutics 11 (5), 229, 2019 | 25 | 2019 |
| Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 protein M Malm, K Tamminen, T Vesikari, V Blazevic Molecular Immunology 78, 27-37, 2016 | 20 | 2016 |
| Mucosal antibodies induced by intranasal but not intramuscular immunization block norovirus GII. 4 virus-like particle receptor binding K Tamminen, M Malm, T Vesikari, V Blazevic Viral immunology 29 (5), 315-319, 2016 | 20 | 2016 |
| Immunological cross-reactivity of an ancestral and the most recent pandemic norovirus GII. 4 variant K Tamminen, M Malm, T Vesikari, V Blazevic Viruses 11 (2), 91, 2019 | 15 | 2019 |
| Pre-existing Immunity to Norovirus GII-4 Virus-Like Particles Does Not Impair de Novo Immune Responses to Norovirus GII-12 Genotype K Tamminen, L Huhti, T Vesikari, V Blazevic Viral Immunology 26 (2), 167-170, 2013 | 15 | 2013 |
| Norovirus-specific mucosal antibodies correlate to systemic antibodies and block norovirus virus-like particles binding to histo-blood group antigens K Tamminen, M Malm, T Vesikari, V Blazevic Clinical Immunology 197, 110-117, 2018 | 13 | 2018 |
| Rotavirus VP6 adjuvant effect on norovirus GII. 4 virus-like particle uptake and presentation by bone marrow-derived dendritic cells in vitro and in vivo K Tamminen, S Heinimäki, T Vesikari, V Blazevic Journal of immunology research 2020, 2020 | 12 | 2020 |
| Early‐life exposure to common virus infections did not differ between coeliac disease patients and controls K Simre, O Uibo, A Peet, L Puustinen, S Oikarainen, K Tamminen, ... Acta Paediatrica 108 (9), 1709-1716, 2019 | 11 | 2019 |
| A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like … I Leroux-Roels, C Maes, J Joye, B Jacobs, F Jarczowski, A Diessner, ... Frontiers in Immunology 13, 1021500, 2022 | 10 | 2022 |
